Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine for Decreasing Chimerism in MDS or AML After Stem Cell Transplant
NCT03850418Phase 2Recruiting
- Sponsor
- Henry Ford Health
- Start
- Jul 2019
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of azacitidine in Myeloid malignancy, sponsored by Henry Ford Health. Started Jul 2019; status: recruiting.
02
Drugs
azacitidine
03
Conditions
Myeloid malignancy
Beyond the preview
Go deeper on NCT03850418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03850418.